What is Taximcef?
Taximcef injection is used to treat bacterial infections in many different parts of the body. Taximcef is also given before, during, and after certain types of surgery to prevent infections.
Taximcef injection belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, Taximcef will not work for colds, flu, or other virus infections.
Taximcef is to be given only by or under the supervision of your doctor.
Taximcef indications
Treatment
Taximcef (Taximcef for injection) for Injection USP and Dextrose Injection is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below.
- Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Streptococcus pyogenes* (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli, Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae, Proteus mirabilis, Serratia marcescens*, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa).
- Genitourinary infections. Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis, Staphylococcus aureus* (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Proteus mirabilis, Proteus vulgaris*, Providencia stuartii, Morganella morganii*, Providencia rettgeri*, Serratia marcescens and Pseudomonas species (including P. aeruginosa).
- Gynecologic infections, including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis, Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli, Proteus mirabilis, Bacteroides species (including Bacteroides fragilis*), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum*).
Taximcef (Taximcef for injection), like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added.
- Bacteremia/Septicemia caused by Escherichia coli, Klebsiella species, and Serratia marcescens, Staphylococcus aureus and Streptococcus species (including S. pneumoniae).
- Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis, Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli, Citrobacter species (including C. freundii*), Enterobacter species, Klebsiella species, Proteus mirabilis, Proteus vulgaris*, Morganella morganii, Providencia rettgeri*, Pseudomonas species, Serratia marcescens, Bacteroides species, and anaerobic cocci (including Peptostreptococcus* species and Peptococcus species).
- Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli, Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus* species and Peptococcus* species) Proteus mirabilis*, and Clostridium species*.
- Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes*), Pseudomonas species (including P. aeruginosa*), and Proteus mirabilis*.
- Central nervous system infections, e.g., meningitis and ventriculitis, caused by Neisseria meningitidis, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae* and Escherichia coli*.
(*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections.
Although many strains of enterococci (e.g., E. faecalis) and Pseudomonas species are resistant to Taximcef (Taximcef for injection) sodium in vitro, Taximcef (Taximcef for injection) has been used successfully in treating patients with infections caused by susceptible organisms.
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to Taximcef (Taximcef for injection). Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.
In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Taximcef (Taximcef for injection) may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if Taximcef (Taximcef for injection) is used concomitantly with an aminoglycoside.
Prevention
The administration of Taximcef (Taximcef for injection) preoperatively reduces the incidence of certain infections in patients undergoing surgical procedures (e.g., abdominal or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or potentially contaminated.
In patients undergoing cesarean section, intraoperative (after clamping the umbilical cord) and postoperative use of Taximcef (Taximcef for injection) may also reduce the incidence of certain postoperative infections. See DOSAGE AND ADMINISTRATION section.
Effective use for elective surgery depends on the time of administration. To achieve effective tissue levels, Taximcef (Taximcef for injection) should be given 1/2 or 1 1/2 hours before surgery. See DOSAGE AND ADMINISTRATION section.
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as with a non-absorbable antibiotic (e.g., neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism so that appropriate therapy may be instituted.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Taximcef (Taximcef for injection) for Injection USP and Dextrose Injection and other antibacterial drugs, Taximcef (Taximcef for injection) for Injection USP and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
How should I use Taximcef?
Use Taximcef as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Taximcef is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Taximcef at home, a health care provider will teach you how to use it. Be sure you understand how to use Taximcef. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
- Do not use Taximcef if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
- To clear up your infection completely, use Taximcef for the full course of treatment. Keep using it even if you feel better in a few days.
- Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
- If you miss a dose of Taximcef, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Taximcef.
Uses of Taximcef in details
Use: Labeled Indications
Bacteremia/Septicemia: Treatment of bacteremia/septicemia caused by Escherichia coli, Klebsiella species, and Serratia marcescens, Staphylococcus aureus and Streptococcus species (including Streptococcus pneumoniae).
Bone or joint infections: Treatment of bone or joint infections caused by S. aureus (penicillinase and nonpenicillinase producing strains), Streptococcus species (including Streptococcus pyogenes), and Proteus mirabilis.
CNS infections: Treatment of CNS infections (eg, meningitis, ventriculitis) caused by Neisseria meningitidis, Haemophilus influenzae, S. pneumoniae, Klebsiella pneumoniae, and E. coli.
Genitourinary infections: Treatment of genitourinary infections, including urinary tract infections (UTIs), caused by Staphylococcus epidermidis, S. aureus (penicillinase and nonpenicillinase producing), Citrobacter species, Enterobacter species, E. coli, Klebsiella species, P. mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Providencia rettgeri, and S. marcescens
Gynecologic infections: Treatment of gynecologic infections, including pelvic inflammatory disease, endometritis, and pelvic cellulitis, caused by S. epidermidis, Streptococcus species, Enterobacter species, Klebsiella species, E. coli, P. mirabilis, Bacteroides species (including Bacteroides fragilis), Clostridium species, and anaerobic cocci (including Peptostreptococcus and Peptococcus species) and Fusobacterium species (including Fusobacterium nucleatum).
Intraabdominal infections: Treatment of intraabdominal infections, including peritonitis caused by Streptococcus species, E. coli, Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species), P. mirabilis, and Clostridium species.
Lower respiratory tract infections: Treatment of lower respiratory tract infections, including pneumonia, caused by S. pneumoniae, S. pyogenes (group A streptococci) and other streptococci (excluding enterococci, [eg, Enterococcus faecalis]), S. aureus (penicillinase and nonpenicillinase producing), E. coli, Klebsiella species, H. influenzae (including ampicillin-resistant strains), H. parainfluenzae, P. mirabilis, S. marcescens, Enterobacter species, and indole-positive Proteus
Skin and skin structure infections: Treatment of skin and skin structure infections caused by S. aureus (penicillinase and nonpenicillinase producing), S. epidermidis, S. pyogenes (group A streptococci) and other streptococci, Acinetobacter species, E. coli, Citrobacter species (including Citrobacter freundii), Enterobacter species, Klebsiella species, P. mirabilis, P. vulgaris, M. morganii, P. rettgeri, S. marcescens, Bacteroides species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species).
Surgical prophylaxis: Reduce the incidence of certain infections in patients undergoing surgical procedures (eg, abdominal or vaginal hysterectomy, GI and GU tract surgery) that may be classified as contaminated or potentially contaminated; reduce the incidence of certain postoperative infections in patients undergoing cesarean section.
Off Label Uses
Acute bacterial rhinosinusitis
Based on the Infectious Diseases Society of America (IDSA) guidelines for acute bacterial rhinosinusitis (ABRS) in children and adults, Taximcef (among other cephalosporins) is effective and recommended (in combination with clindamycin) for the treatment of ABRS.
Bite wound (animal)
Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTI), Taximcef, in combination with clindamycin or metronidazole for anaerobic coverage, is an effective and recommended alternative for treatment of bite wounds.
Gonococcal, disseminated infection (arthritis and arthritis-dermatitis syndrome)
Based on Centers for Disease Control and Prevention (CDC) sexually transmitted diseases treatment guidelines, Taximcef plus azithromycin is considered an alternative regimen for the treatment of arthritis and arthritis-dermatitis syndrome associated with disseminated gonococcal infection. Ceftriaxone plus azithromycin is the preferred regimen. Taximcef should not be used for the treatment of gonococcal meningitis and endocarditis due to disseminated gonococcal infection.
Lyme disease
Based on the Infectious Diseases Society of America (IDSA) guidelines for the clinical assessment, treatment, and prevention of Lyme disease, Taximcef is an effective and recommended alternative agent for the treatment of acute and late neurologic disease, carditis, and arthritis.
Skin and soft tissue necrotizing infections
Based on the Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of skin and soft tissue infections (SSTI), Taximcef, in combination with metronidazole or clindamycin, is an effective and recommended alternative for empiric treatment of mixed (polymicrobial) necrotizing infections of the skin, fascia, and muscle; in combination with doxycycline, Taximcef is effective and recommended for treatment of necrotizing infections of the skin, fascia, and muscle due to Vibrio vulnificus.
Taximcef description
Taximcef is a fourth-generation cephalosporin antibiotic developed in 1994. Taximcef has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both Gram-negative and Gram-positive organisms than third-generation agents. Taximcef is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.
Taximcef dosage
Treatment of Uncomplicated Infections: Adults: Usual Dose: 1 g IM or IV every 12 hrs. Moderate to severe infections usually respond to 1-2 g IM/IV every 8 hrs, but some infections (eg, septicemia) should be treated with 2 g IV every 6-8 hrs. Severe or life-threatening infections may require 2 g IV every 4 hrs.
Meningitis and Other CNS Infections: For the treatment of meningitis or other CNS infections caused by susceptible bacteria, the usual adult dosage of Taximcef is 2 g IV every 6 hrs for 7-21 days.
Gonorrhea and Associated Infections: Adults and Adolescents: Uncomplicated Urethral, Cervical or Rectal Gonorrhea caused by N. gonorrhoeae: 500 mg IM as a single dose.
Disseminated Gonorrhea: 1 g IV every 8 hrs.
Parenteral Taximcef should be continued for 24-48 hrs after improvement begins; therapy can then be switched to oral cefixime or oral cefpodoxime to complete at least 1 wk of therapy.
Lyme Disease: If Taximcef is used for the treatment of early lyme disease in adults with acute neurologic disease manifested by meningitis or radiculopathy, the recommended dose is 2 g IV every 8 hrs for 14 days (range: 10-28 days).
If Taximcef is used when a parenteral regimen is indicated for the treatment of lyme carditis in patients with atrioventricular (AV) heart block and/or myopericarditis associated with early lyme disease, the recommended dose is 2 g IV every 8 hrs for 14 days (range: 14-21 days).
If Taximcef is used when a parenteral regimen is indicated for the treatment of lyme arthritis in patients with evidence of neurologic disease or when arthritis has not responded to an oral regimen, the recommended dose is 2 g IV every 8 hrs for 14 days (range: 14-28 days).
If Taximcef is used for the treatment of late neurologic lyme disease affecting the CNS or peripheral nervous system, the recommended dose is 2 g IV every 8 hrs for 14 days (range: 14-28 days).
Respiratory Tract Infections: For the treatment of community-acquired pneumonia (CAP) in adults who are hospitalized for inpatient treatment, Taximcef usually is given in a dosage of 1 g every 6-8 hrs.
If used for empiric treatment of CAP, Taximcef is used in conjunction with other anti-infectives.
Children and Infants with >50 kg body weight: The usual daily adult dosage is given, but dosage should not exceed 12 g daily.
Premature or Full-Term Neonates 1-4 week: The usual dosage of Taximcef is 50 mg/kg every 8 hrs; Neonates <1 week 50 mg/kg every 12 hrs.
Administration: Taximcef sodium is administered IV or by deep IM injection.
Intermittent IV Injection: For direct intermittent IV administration, 10 mL of sterile water for injection should be added to a vial labeled as containing Taximcef 500 mg, 1 g or 2 g to provide a solution approximately containing Taximcef 50, 95, or 180 mg/mL, respectively. A solution of Taximcef 1 g/14 mL of sterile water for injection is isotonic. The appropriate dose may then be injected directly into a vein over a 3- to 5-min period or slowly into the tubing of a freely flowing compatible IV solution. Taximcef should not be injected IV over less than 3 min.
Intermittent or Continuous IV Infusion: For intermittent or continuous IV infusion, 50 or 100 mL of sodium chloride 0.9% injection or dextrose 5% injection should be added to an infusion bottle labeled as containing Taximcef 1 or 2 g, or alternatively, reconstituted solutions of Taximcef may be further diluted with 50 mL to 1 L of a compatible IV solution.
Intermittent IV infusions of Taximcef are generally infused over 20-30 min; solutions should preferably be infused via butterfly or scalp vein-type needles. Other IV solutions flowing through a common administration tubing or site should be discontinued while Taximcef is being infused unless the solutions are known to be compatible and the flow-rate is adequately controlled.
IM Injection: IM injections of Taximcef are prepared by adding 2, 3 or 5 mL of sterile or bacteriostatic water for injection to a vial labeled as containing Taximcef 500 mg, 1 g or 2 g. Resultant solutions approximately contain Taximcef 230, 300 or 330 mg/mL, respectively. IM injections should be administered deeply into a large muscle mass eg, the upper outer quadrant of the gluteus maximus; aspiration should be performed to avoid inadvertent injection into a blood vessel. The manufacturers state that if an IM dose of Taximcef 2 g is indicated, the dose should be divided and administered at 2 different injection sites. However, because large IM doses of Taximcef may be painful, some clinicians recommend that large doses of the drug be given IV.
Taximcef interactions
See also:
What other drugs will affect Taximcef?
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
Probenecid interferes with the renal tubular transfer of Taximcef, decreasing the total clearance of Taximcef by approximately 50% and increasing the plasma concentrations of Taximcef. Administration of Taximcef in excess of 6 grams/day should be avoided in patients receiving probenecid.
Drug/Laboratory Test Interactions
Cephalosporins, including Taximcef sodium, are known to occasionally induce a positive direct Coombs' test.
A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict's or Fehling's solution or with CLINITEST® tablets), but not with enzyme-based tests for glycosuria. (e.g., CLINISTIX® or TesTape®). There are no reports in published literature that link elevations of plasma glucose levels to the use of Taximcef.
Taximcef side effects
See also:
What are the possible side effects of Taximcef?
Taximcef (Taximcef for injection) is generally well tolerated. The most common adverse reactions have been local reactions following IV injection. Other adverse reactions have been encountered infrequently.
The most frequent adverse reactions (greater than 1%) are:
Local (4.3%)— Injection site inflammation with IV administration.
Hypersensitivity (2.4%)—Rash, pruritus, fever, eosinophilia and less frequently urticaria and anaphylaxis.
Gastrointestinal (1.4%)—Colitis, diarrhea, nausea, and vomiting.
Symptoms of pseudomembranous colitis can appear during or after antibiotic treatment.
Nausea and vomiting have been reported rarely.
Less frequent adverse reactions (less than 1%) are:
Cardiovascular System—Potentially life-threatening arrhythmias following rapid (less than 60 seconds) bolus administration via central venous catheter have been observed.
Hematologic System—Neutropenia, transient leukopenia, eosinophilia, thrombocytopenia and agranulocytosis have been reported. Some individuals have developed positive direct Coombs Tests during treatment with Taximcef (Taximcef for injection) and other cephalosporin antibiotics. Rare cases of hemolytic anemia have been reported.
Genitourinary System—Moniliasis, vaginitis.
Central Nervous System—Headache, encephalopathy.
Liver—Transient elevations in SGOT, SGPT, serum LDH, and serum alkaline phosphatase levels have been reported.
Kidney—As with some other cephalosporins, interstitial nephritis and transient elevations of BUN and creatinine have been occasionally observed with Taximcef (Taximcef for injection).
Cutaneous—As with other cephalosporins, isolated cases of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported.
Cephalosporin Class Labeling
In addition to the adverse reactions listed above which have been observed in patients treated with Taximcef (Taximcef for injection) sodium, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics: allergic reactions, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage, and false-positive test for urinary glucose.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. See DOSAGE AND ADMINISTRATION and OVERDOSAGE. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Taximcef contraindications
See also:
What is the most important information I should know about Taximcef?
You should not use this medication if you are allergic to Taximcef or to similar antibiotics, such as cefdinir (Omnicef), cefprozil (Cefzil), cefuroxime (Ceftin), cephalexin (Keflex), and others.
Before using this medication, tell your doctor if you are allergic to any drugs (especially penicillin). Also tell your doctor if you have liver or kidney disease, diabetes, a stomach or intestinal disorder, or a heart rhythm disorder.
Use this medication for the entire length of time prescribed by your doctor. Your symptoms may get better before the infection is completely treated. Taximcef will not treat a viral infection such as the common cold or flu.
Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or has blood in it, call your doctor. Do not use any medicine to stop the diarrhea unless your doctor has told you to.
This medication can cause unusual results with certain lab tests for glucose (sugar) in the urine. Tell any doctor who treats you that you are using Taximcef.
Active ingredient matches for Taximcef:
Cefotaxime in Vietnam.
| Unit description / dosage (Manufacturer) | Price, USD |
| Taximcef 1 g x 1 Bottle boät keøm tube nöôùc caát | |
List of Taximcef substitutes (brand and generic names): | |
| Taximax (Indonesia) | |
| Taximax 375 mg Injection (Alkem Laboratories Ltd) | $ 0.25 |
| Taxime 1.0 Inj (im / Iv) | |
| Taximed (Czech Republic) | |
| Taximmed (Vietnam) | |
| Taximmed 1 g x 1 Box pha tieГўm | |
| Taximodel (Egypt) | |
| TAXIROM | |
| TAXIROM 500MG INJECTION 1 vial / 1 injection each (Rhombus Pharma Pvt Ltd) | $ 0.28 |
| Taxobid | |
| Taxobid 250 mg Injection (Zydus Cadila Healthcare Ltd) | $ 0.17 |
| Taxobid 500 mg Injection (Zydus Cadila Healthcare Ltd) | $ 0.28 |
| Taxobid 1000 mg Injection (Zydus Cadila Healthcare Ltd) | $ 0.48 |
| Taxocef (Turkey) | |
| TAXOPEN | |
| TAXOPEN 1GM INJECTION 1 vial / 1 injection each (Morepen Laboratories Ltd) | $ 0.44 |
| Taxtam | |
| Taxtam 500+250 Injection (Critical Care (Orchid Chemicals & Pharmaceuticals Ltd.)) | $ 0.33 |
| Taxtam 1000+500 Injection (Critical Care (Orchid Chemicals & Pharmaceuticals Ltd.)) | $ 0.55 |
| TAXTAM 1000MG/500MG INJECTION 1 vial / 1 injection each (Critical Care (Orchid Chemicals & Pharmaceuticals Ltd.)) | $ 0.40 |
| Taxtam 1000 mg/500 mg Injection (Critical Care (Orchid Chemicals & Pharmaceuticals Ltd.)) | $ 0.40 |
| Tazon (India) | |
| Tazon 250 mg Injection (Elfin Pharma (P) Ltd) | $ 0.19 |
| TAZON 4000MG/500MG INJECTION (Elfin Pharma (P) Ltd) | $ 5.42 |
| Tebruxim (Mexico) | |
| Tecnoxima (Mexico) | |
| Terasep (Argentina) | |
| Tirdicef (Indonesia) | |
| Tirdicef / vial 1 g x 1's (Bernofarm) | $ 12.69 |
| Tirotax (Georgia, Hungary, Oman, Poland) | |
| Injectable; Injection; Cefotaxime Sodium 500 mg (Sandoz) | |
| Injectable; Injection; Cefotaxime Sodium 1 g (Sandoz) | |
| Tirotax 1 g x 1 Bottle (Sandoz) | |
| Tirotax 0.05g (Oman) | |
| Tirotax 1g (Oman) | |
| Tirotax 2g (Oman) | |
| Tizoxim (Argentina, Peru) | |
| Tizoxim 50 mg x 1 Bottle Г±eГҐ pha 30mL (Richmond) | |
| Tizoxim 100 mg x 1 Blister x 10 Tablet (Richmond) | |
| Tizoxim 200 mg x 1 Blister x 10 Tablet (Richmond) | |
| Tolycar (Serbia) | |
| Tot (India) | |
| Tot 250mg INJ / 1 (Biomax Biotechnics) | $ 0.19 |
| 250 mg x 1's (Biomax Biotechnics) | $ 0.19 |
| Tot 250 mg Injection (Biomax Biotechnics) | $ 0.19 |
| Tot 200+500 Tablet (Biomax Biotechnics) | $ 0.06 |
| Totam (South Africa) | |
| Totam 1 Mg | |
| TOX (LABORATE) | |
| TOX 1GM INJECTION 1 vial / 5 ML injection each (Laborate Pharmaceuticals India Ltd) | $ 0.33 |
| TOX 250MG INJECTION 1 vial / 2 ML injection each (Laborate Pharmaceuticals India Ltd) | $ 0.16 |
| TOX 500MG INJECTION 1 vial / 1 injection each (Laborate Pharmaceuticals India Ltd) | $ 0.21 |
| Traxime (Myanmar) | |
| Tritaxin (India) | |
| Tritaxin 1g VIAL / 1 (Health Biotech) | $ 0.32 |
See 1633 substitutes for Taximcef | |
References
- PubChem. "cefotaxime". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "cefotaxime". http://www.drugbank.ca/drugs/DB00493 (accessed September 17, 2018).
- MeSH. "Anti-Bacterial Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Taximcef are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Taximcef. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
